4.0 Article

The Effect of Blood Glucose Self-Monitoring Among Inmates With Diabetes

Journal

JOURNAL OF CORRECTIONAL HEALTH CARE
Volume 21, Issue 4, Pages 343-354

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1177/1078345815599782

Keywords

diabetes mellitus; blood glucose self-monitoring; prisoners; hemoglobin A1c

Funding

  1. Amylin Pharmaceuticals
  2. AstraZeneca
  3. Eli Lilly Co.
  4. GlaxoSmithKline
  5. Merck Co.
  6. Novo Nordisk
  7. Proctor Gamble Co.
  8. Prodigy Diabetes Care

Ask authors/readers for more resources

The increasing prevalence and risk of complications from diabetes necessitate patient participation and attentiveness to select appropriate foods, perform regular physical activity, and be active in diabetes management and self-maintenance. Diabetes is often largely asymptomatic; consequently, early diagnosis and treatment are necessary. Inmates are a unique population challenged by the increased prevalence of chronic conditions including diabetes. Diabetes standards for inmates contain diagnostic and treatment management guidelines that incorporate personal glucose monitoring for insulin users. In December 2009, the Federal Bureau of Prisons initiated a program to distribute glucose meters to insulin-dependent inmates to facilitate self-monitoring blood glucose. The purpose of this study was to evaluate the effect of these glucose meters on hemoglobin A1c levels.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available